BRIEF published on 09/28/2026 at 19:56, 1 month 2 days ago GENFIT annonce ses résultats financiers et ses développements stratégiques pour le premier semestre 2026 GENFIT Financials Développements Biopharmaceutiques Diagnostics MASH Accord Ipsen Pipeline De R&D
BRIEF published on 09/28/2026 at 19:56, 1 month 2 days ago GENFIT Announces H1 2026 Financial Performance and Strategic Developments R&D Pipeline GENFIT Financials Biopharmaceutical Developments MASH Diagnostics Ipsen Agreement
PRESS RELEASE published on 09/28/2026 at 19:51, 1 month 2 days ago GENFIT : Résultats financiers du premier semestre 2026 et point sur les activités de la Société
PRESS RELEASE published on 09/28/2026 at 19:51, 1 month 2 days ago GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update GENFIT reports first-half 2026 financial results and provides corporate update including significant revenue growth, strategic developments and future milestones Revenues Financial Results Corporate Update Milestones GENFIT
BRIEF published on 09/14/2026 at 18:20, 1 month 16 days ago GENFIT Initiates Phase 2 Trials for Nangibotide in ACLF Phase 2 Trials Liver Diseases GENFIT ACLF Nangibotide
BRIEF published on 09/14/2026 at 18:20, 1 month 16 days ago GENFIT lance des essais de phase 2 pour le nangibotide dans l'insuffisance hépatique aiguë sur cirrhose. Essais De Phase 2 GENFIT ACLF Maladies Du Foie Nangibotide
PRESS RELEASE published on 09/14/2026 at 18:15, 1 month 16 days ago GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLF GENFIT strengthens pipeline with acquisition of nangibotide for ACLF treatment in Phase 2 trial. Positive efficacy and safety signals observed. Details at The Liver Meeting in Denver, November 2026 Phase 2 Trial GENFIT ACLF Nangibotide The Liver Meeting
BRIEF published on 09/11/2026 at 07:35, 1 month 20 days ago GENFIT is included in the CAC Mid 60 and SBF 120 indices Biopharmaceutical SBF 120 GENFIT CAC Mid 60 Stock Market Indices
BRIEF published on 09/11/2026 at 07:35, 1 month 20 days ago GENFIT intègre les indices CAC Mid 60 et SBF 120 Biopharmaceutique SBF 120 GENFIT Indices Boursiers CAC Mid 60
BRIEF published on 09/11/2026 at 07:35, 1 month 20 days ago GENFIT Joins CAC Mid 60 and SBF 120 Indices Institutional Investors Market Capitalization SBF 120 CAC Mid 60 GENFIT Inclusion
Published on 10/30/2026 at 23:35, 1 day 14 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 15 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 1 day 19 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 23 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 3 hours 57 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 9 hours 32 minutes ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 21 hours 57 minutes ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 15 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 1 day 15 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 1 day 15 hours ago Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie
